Source comparison
Comparisons: Melanotan II, Afamelanotide, and Bremelanotide
Because the internet routinely blurs these molecules together, disentangling them is one of the most useful things this article can do. All three are melanocortin agonists derived from the same α-MSH scaffold, but they differ dramatically in selectivity, devel
This comparison does not assign a generated winner or score.
- Because the internet routinely blurs these molecules together, disentangling them is one of the most useful things this article can do. All three are melanocortin agonists derived from the same α-MSH scaffold, but they differ dramatically in selectivity, development history, evidence base, and legal status—and only one of them has ever earned an approval for anything.
- Structure
- Cyclic heptapeptide
- Linear 13-aa α-MSH analogue
- Cyclic MT-II metabolite (deamidated)
- Receptor profile
- Non-selective (MC1/3/4/5R)
- More MC1R-selective
- MC1R/MC4R, favors MC4R action
- Approved indication
- None
- Prevent phototoxicity in EPP
- Hypoactive sexual desire disorder (women)
- Delivery in approved use
- N/A (unapproved)
- Controlled subcutaneous implant, in-clinic
- Prefilled subcutaneous auto-injector
- Human trial evidence
- None for disease prevention
- Randomized, placebo-controlled (NEJM)
- Randomized phase 3 program
- Regulatory stance
- Warned against; illegal to sell for use
- FDA-approved 2019; EMA-approved
- FDA-approved 2019
- Afamelanotide is the instructive comparator for the disease-prevention question, because it is the melanocortin agonist that actually went through rigorous development. Two multicenter, randomized, double-blind, placebo-controlled trials—74 patients in the European Union and 94 in the United States—tested 16 mg subcutaneous implants in adults with erythropoietic protoporphyria (EPP), a rare inherited disorder in which sunlight causes severe, disabling phototoxic pain. Those trials were published in the New England Journal of Medicine in 2015 and showed that afamelanotide increased pain-free light exposure and shortened recovery from phototoxic reactions.11 On that basis, the FDA approved afamelanotide (Scenesse) in October 2019, and it is also authorized in the EU.12 Note carefully what this approval is and is not: it is prevention of a light-triggered symptom in a rare metabolic disease, delivered as a controlled clinical implant. It is not an approval for skin-cancer prevention, and
- The afamelanotide story also demolishes a common rhetorical move—”melanocortin peptides are FDA-approved, so Melanotan II is basically legitimate.” That inference fails on every axis. The approved molecule is chemically distinct and more receptor-selective; it went through controlled trials Melanotan II never underwent; it is manufactured to pharmaceutical standards and administered by clinicians rather than reconstituted at a kitchen table; and its approved use is a narrow orphan indication, not tanning or cancer prevention. If anything, the contrast underlines how much evidence and quality control separate a real melanocortin therapy from a research chemical.
- Bremelanotide (PT-141) completes the picture. It is literally a metabolite of Melanotan II—the deamidated, ring-opened breakdown product—and it was developed specifically for its central MC4R activity on sexual desire, gaining FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. It has essentially no role as a tanning or photoprotective agent, and its existence explains why Melanotan II users frequently report sexual side effects: they are dosing a compound whose own metabolite is a licensed libido drug. Some users combine the two, a practice discussed at dosagepeptide.com’s peptide stacks overview, but combining an unapproved compound with anything compounds the underlying safety and legality problems rather than resolving them. The broad peptide dosage index catalogs how these melanocortin agents are characterized in research-education terms. The bottom line across all three molecules: shared ancestry does not mean shared evidence, and Melanotan II is th